


Astraveus Strengthens Leadership Team and Board
Jean-Paul Mangeolle joins as Chairman of the Board of Directors
…

Oxolife’s CEO Agnès Arbat receives prestigious EU Women Innovators Prize
Barcelona, Spain – 9 April 2025: Oxolife, the female fertility…

Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer
Revolutionary ‘off-the-shelf’ cancer vaccine designed…

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council
Xeltis is one of only seven companies to successfully pass…

Novo Holdings posts record Total Income and Investment Returns of DKK 60 billion (€8.0 billion) in 2024, with the Investment Portfolio delivering above-benchmark returns, alongside strong growth at the Novo Group companies
Copenhagen, Denmark – Novo Holdings today announced its financial…

Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025
Presentation of Phase I clinical results from DT-9081, an…

Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE:…

Gergely Sved appointed CEO of Ellab
27 March 2025 Hillerød, Denmark – Ellab, the leading provider…

Poolbeg to Participate in Key Conferences in March and April 2025
Poolbeg to present at Master Investor Show, BioTrinity &…

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata
Unique siRNA platform, developed with Nobel Prize Laureate…

Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
Investment addresses the need for disease-modifying therapies…

Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer
Pioneering cancer immunology company Asgard strengthens leadership…

Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
Promising data in the clinical trial with HDP-101 in multiple…

Poolbeg Pharma plc – POLB 001 Patent Granted in Korea
Grant further strengthens Poolbeg's global intellectual property…

iOnctura commences randomized Phase II study in metastatic uveal melanoma
First patient dosed in Phase II OCULE-01 study with roginolisib,…

Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases
DT-9046 is a highly differentiated first-in-class biased negative…

Infinitopes Strengthens Board with Two Biotech Leaders to Advance Precision Immunotherapies into the Clinic
Visionary sector leaders Dan Menichella and Jo Brewer, PhD…

BioClec launches with backing from Sofinnova Partners to pioneer breakthrough Alzheimer’s Therapies
Co-founded by Dr. Marco Colonna, a global expert in neuroimmunology…

Forth Therapeutics launches with backing from Sofinnova Partners to revolutionize fibrosis treatments
Cutting-edge research from Professor Neil Henderson at the…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York